Genetic Polymorphism at CCL5 Is Associated With Protection in Chagas’ Heart Disease: Antagonistic Participation of CCR1+ and CCR5+ Cells in Chronic Chagasic Cardiomyopathy

Products Related to West Nile, Dengue, Malaria, T.B, Chikungunya, Sars, Zika

Product# 20004: Recombinant T. cruzi (Chagas) Composite Antigen A13, B13,H49,1F8 Antigen (E.coli)

Product# 20002: Recombinant T. cruzi (Chagas) Microtubule-Associated Protein, MAP

Product# 20001:  Recombinant T. cruzi (Chagas) Complement Regulatory Protein, CRP (Prokaryotic)

 

 

Abstract

Figure 1

CCL5 levels and association with disease severity, genotypes and left ventricular ejection fraction (LVEF) in T. cruzi-infected patients. (A) CCL5 levels in the serum of seronegative noninfected (NI) individuals and individuals who were seropositive for Chagas disease (CD); ***P < 0.001 (Student’s t-test). (B) CCL5 concentrations in the serum of CD patients grouped as A (asymptomatic), B1 [mild chronic chagasic cardiomyopathy (CCC)], or C (severe CCC) (analysis of variance, Bonferroni posttest). (C) Comparison of CCL5 serum levels according to the absence (CC) or presence of rs2107538 allele T (Mann–Whitney test). (D) Correlation between the CCL5 serum concentrations and LVEF in patients; P = 0.8078, r² = 0.0006 (linear regression).

CCL5 Levels Are Increased in Heart Tissue, and an Altered Balance of CCR1/CCR5 Expression on CD8⁺ T Cells Is Detected in Chronically T. cruzi-Infected Mice

To shed light on the contribution of CCL5 and its receptors CCR1 and CCR5 in Chagas heart disease, we used a model of CCC that presents fibrosis, CD8-enriched myocarditis, myocardial injury and electrical and functional abnormalities (27, 28, 41). An increased concentration of CCL5 was detected in the heart tissue of chronically (120 dpi) T. cruzi-infected mice (Figure ​(Figure2A).2A). In the spleen, most of the CD8⁺ cells were T cells (Figure S3A in Supplementary Material). The frequencies of CD8⁺TCR⁺ cells were similar in splenocytes of NI and chronically T. cruzi-infected mice (Figure ​(Figure2B).2B). However, in infected mice, an altered balance of CCR1 and CCR5 expression was achieved, with a significant reduction in CCR1⁺ and an increase in CCR1⁺CCR5⁺ and CCR5⁺ cell frequencies among CD8⁺ T cells (Figure ​(Figure2B).2B). Additionally, the increase in the frequencies of CCR5⁺ CD8⁺TCR⁺ cells showed a moderate negative correlation (r² = 0.424) with the decreased frequencies of CCR1⁺ CD8⁺TCR⁺ cells (Figure S3B in Supplementary Material).

 

 

Figure 2

CCL5 levels and CCR1 and CCR5 expression in CD8⁺ T cells and CD14⁺ macrophages of T. cruzi-infected C57BL/6 mice. Mice were infected with 100 trypomastigote forms of the Colombian T. cruzi strain and analyzed at 120 days postinfection. The heart was removed, proteins were extracted, and CCL5 concentrations were estimated by enzyme-linked immunosorbent assay. Splenocytes were collected and stained for intracellular cytokines (TNF, IL-10) and surface cell markers (CD8, CD14, CCR1, CCR5). (A) CCL5 levels in the heart tissue extracts of T. cruzi-infected mice compared to noninfected (NI) controls. (B) Percentages of total CD8⁺ T cells and CD8⁺ T cells expressing CCR1 and/or CCR5 in the spleen of NI and T. cruzi-infected mice. (C) The table shows percentages of total CD14⁺ macrophages. Graphs show the frequencies of CD14⁺ macrophages expressing CCR1 or CCR5 and CD14⁺ macrophages expressing TNF, TNF/IL-10, or IL-10 in the spleen of NI and T. cruzi-infected mice. (D) Pie charts represent the fractions of CCR1⁺ or CCR5⁺ CD14⁺ macrophages carrying each of the intracellular cytokine phenotypes shown in the legend. Graphs show the frequencies of CCR1⁺ or CCR5⁺ CD14⁺ macrophages expressing TNF, TNF/IL-10 or IL-10. Data represent two independent experiments with three NI and five to seven infected mice [*P < 0.05, **P < 0.01, ***P < 0.001, T. cruzi-infected mice vs NI (Student’s t-test)].

Regarding the inflammatory/regulatory profiles, in NI sex- and age-matched control mice, CCR1⁺CD8⁺ T cells showed a high frequency of IL-10⁺ cells, whereas CCR5⁺ CD8⁺ T cells presented a more balanced TNF/IL-10 profile (Figure S4 in Supplementary Material). In chronically T. cruzi-infected mice (120 dpi), TNF⁺ cells predominated in both the CCR1⁺ and CCR5⁺ CD8⁺ T-cell populations, while CCR5⁺ cells presented a higher frequency of TNF⁺ cells compared with CCR1⁺ CD8⁺ T cells. Moreover, the TNF/IL-10 ratio was higher in CCR5⁺ compared with CCR1⁺ CD8⁺ T cells of T. cruzi-infected mice (Figure S4 in Supplementary Material).

Antagonist IL-10 and TNF Phenotypes Are Sustained in CCR1⁺ and CCR5⁺ Macrophages of Chronically T. cruzi-Infected Mice

The frequencies of splenic CD14⁺ macrophages remained similar in T. cruzi-infected mice compared with those in NI controls (Figure ​(Figure2C).2C). In NI and T. cruzi-infected mice, the CD14⁺ cells were mostly CD11c^neg, Ly6C^neg, and CD45R⁺F4/80⁺, either CD11b⁺ or CD11b^neg (Figures S5A,B in Supplementary Material). In comparison to NI age-matched controls, in T. cruzi-infected mice, the numbers of splenic CD14⁺ cells were increased (Figure S5C in Supplementary Material). Although CCR1⁺CD14⁺ macrophages predominated in NI and infected mice, a significant decrease in the percentage of CCR1⁺ and an increase in the percentage of CCR5⁺ macrophages were detected in T. cruzi-infected mice (Figure ​(Figure2C).2C). Considering the expression of regulatory IL-10 and inflammatory TNF cytokines, the analysis of single cells revealed that most of the CD14⁺ macrophages were IL-10⁺ in NI mice, whereas there was a significant increase in the percentage of macrophages expressing TNF in T. cruzi-infected mice (Figure ​(Figure2C).2C). Importantly, in NI mice, CCR1⁺ and CCR5⁺ CD14⁺ macrophages presented segregated and antagonist cytokine profiles (Figure S6 in Supplementary Material). In NI mice, CCR1⁺ macrophages were mainly IL-10⁺, whereas CCR5⁺ macrophages were mostly TNF⁺ (Figure ​(Figure2D).2D). In chronically T. cruzi-infected mice, although the percentages of TNF⁺ cells were increased among CCR1⁺ and CCR5⁺ macrophages, the majority of CCR1⁺ macrophages remained IL-10⁺, and most of the CCR5⁺ CD14⁺ macrophages expressed TNF (Figure ​(Figure22D).

Depletion of CCR5 Is Beneficial for Myocardial Injury in Chronically T. cruzi-Infected Mice

To study the contribution of the CCL5–CCR5 axis to heart tissue lesions, we infected CCR5-deficient mice. Interestingly, when infected with 1,000 trypomastigote forms of the Colombian strain, Ccr5^+/+ and Ccr5^−/− mice showed similar survival ratios (Figure ​(Figure3A).3A). At 70 dpi, T. cruzi-infected Ccr5^−/− mice showed reduced myocardial damage, as assessed by CK-MB activity in serum, in comparison to Ccr5^+/+ infected mice (Figure ​(Figure3B).3B). Reduced numbers of circulating parasites and a lower heart tissue parasite load, but increased heart inflammation composed of CD4⁺, CD8⁺, and F4/80⁺ cells, were detected in T. cruzi-infected Ccr5^−/− compared with Ccr5^+/+ mice (Figure S7 in Supplementary Material), suggesting that the quality rather than the intensity may explain the contribution of heart tissue infiltrating cells to tissue damage.

 

 

Figure 3

Effects of CCR5 deficiency on survival and myocardial injury in T. cruzi-infected mice. Mice were infected with 1,000 trypomastigote forms of the Colombian T. cruzi strain and analyzed at 70 days postinfection. (A) Survival curves of T. cruzi-infected Ccr5⁺/⁺ and Ccr5^−/− mice. Deaths were registered weekly. (B) Sera were collected, and CK-MB activity was determined by biochemical assay. Data represent two independent experiments with three noninfected (NI) and five to seven infected mice [*P < 0.05, T. cruzi-infected Ccr5^+/+ mice vs NI; ^#P < 0.05, Ccr5^−/− vs Ccr5^+/+ T. cruzi-infected mice (analysis of variance, Bonferroni posttest)].

CCL5 signals via CCR1, CCR3, and CCR5 in mice (11). When Ccr5^+/+ and Ccr5^−/− mice were infected with 100 trypomastigote forms, all the animals survived, and chronic infection was established. At 120 dpi, the protective effect of CCR5 depletion on myocardial injury was also detected (Figure S8A in Supplementary Material). Furthermore, at this time point of infection, Ccr5^+/+ and Ccr5^−/− mice showed similar CCR1 expression levels in heart tissue and spleen (Figure S8B in Supplementary Material). To address the differential role of CCR5 and CCR1 in heart tissue lesions, chronically T. cruzi-infected Ccr5^−/− mice were treated with Met-RANTES, a selective antagonist for CCR1 and CCR5, but not CCR3, in mice (43), as schematically shown (Figure ​(Figure4A).4A). The treatment of chronically T. cruzi-infected Ccr5^+/+ mice with Met-RANTES partially reduced T. cruzi-elicited splenomegaly (Figure ​(Figure4B)4B) and the cardiac biomarker of serum CK-MB activity (Figure ​(Figure4C)4C) at 150 dpi. Nevertheless, treatment of T. cruzi-infected Ccr5^−/− mice with Met-RANTES reversed the beneficial effect of CCR5 depletion on splenomegaly (Figure ​(Figure4B)4B) and myocardial injury (Figure ​(Figure4C).4C). At 120 dpi, a significant increase in CCL5 concentrations was observed in the heart tissue of chronically T. cruzi-infected Ccr5^−/− mice compared with Ccr5^+/+-infected mice. Met-RANTES treatment did not affect the CCL5 concentrations in the heart tissue of either Ccr5^+/+ or Ccr5^−/−-infected mice (Figure ​(Figure44D).

 

 

Figure 4

Effects of Met-RANTES treatment on splenomegaly, myocardial injury, and CCL5 and TNF concentrations in the heart tissue of T. cruzi-infected mice. (A) Mice were infected with 100 trypomastigote forms of the Colombian T. cruzi strain and treated with Met-RANTES (Met-R, 10 µg/mice) from 120 to 150 days postinfection (dpi). Sera were collected (at 120 and 150 dpi) for estimation of CK-MB activity. Hearts were collected (at 150 dpi) for evaluation of CCL5 and TNF concentrations by enzyme-linked immunosorbent assay (ELISA). (B) The relative weight of the spleen (spleen weight in milligrams/body weight in grams) at 150 dpi. (C) CK-MB activity in serum determined by biochemical assay at 120 (pretherapy) and 150 dpi (posttherapy, Met-R). (D) CCL5 concentrations in extracts of heart tissue evaluated by ELISA at 150 dpi. (E) TNF concentrations in extracts of heart tissue evaluated by ELISA at 150 dpi. Data represent two independent experiments with 3–5 noninfected (NI) and 7–10 infected mice.*P < 0.05, **P < 0.01, ***P < 0.001, T. cruzi-infected mice vs NI; ^#P < 0.05, ^##P < 0.01, and ^###P < 0.001, pretreated vs Met-R-treated; ^&&P < 0.01, ^&&&P < 0.001, Ccr5^−/− vs Ccr5^+/+ T. cruzi-infected mice pretreatment (120 dpi); ^ψP < 0.05, ^ψψP < 0.01, ^ψψψP < 0.001, Ccr5^−/− vs Ccr5^+/+ T. cruzi-infected mice posttreatment (150 dpi) with Met-R (analysis of variance, Bonferroni posttest).

Immunohistochemical characterization revealed that when compared with the respective controls pretherapy, Met-RANTES therapy reduced TNF expression in the heart tissue of Ccr5^+/+ T. cruzi-infected mice but increased TNF expression in the heart tissue of infected Ccr5^−/− mice (Figure S9 Supplementary Material). At 120 dpi (pretherapy), in comparison to age-matched NI mice, elevated TNF concentrations were detected in the heart extracts of T. cruzi-infected Ccr5^+/+ mice (Figure ​(Figure4E).4E). Interestingly, Met-RANTES therapy reduced TNF concentrations in the heart tissue of Ccr5^+/+ mice at 150 dpi (Figure ​(Figure4E).4E). At 120 dpi, compared to Ccr5^+/+ mice, T. cruzi-infected Ccr5^−/− mice presented reduced TNF levels in cardiac tissue (Figure ​(Figure4E).4E). Conversely, after Met-RANTES treatment, increased TNF concentrations were detected in the heart tissue of Ccr5^−/− mice (Figure ​(Figure44E).

CD8⁺CCR1⁺ T-Cell Frequencies and CCL5 Production Are Increased After T. cruzi Antigen Stimulation of Human Peripheral Blood Mononuclear Cells

The previous findings led us to propose that activation of the CCL5–CCR1 axis, but not CCR5, may trigger a beneficial immune response. To test the feasibility of differential activation of the CCL5–CCR1 axis, peripheral blood mononuclear cells of CD patients were stimulated in vitro with parasite antigens and immunophenotyped, and CCL5 levels were measured in the supernatants. The frequencies of CD8⁺CCR1⁺, but not of CD8⁺CCR5⁺, T cells were preserved or even increased among parasite antigen-stimulated blood cells of CD patients (Figure ​(Figure5A).5A). Additionally, the expression density of CCR1, but not CCR5, was upregulated on CD8⁺ T cells from patients with severe Chagas heart disease after antigen stimulation (Figure ​(Figure5A).5A). Increased CCL2 concentrations were detected in the supernatants of antigen-stimulated cells compared with those of nonstimulated cells from patients in groups A, B1, and C (Figure S2E in Supplementary Material). Moreover, increased CCL5 concentrations were detected in the supernatants of antigen-stimulated peripheral blood cells of patients with severe Chagas heart disease (group C) compared with those of nonstimulated cells and cells of patients in group A (Figure ​(Figure55B).

 

 

Figure 5

Expression of CCR1⁺ and CCR5⁺ on CD8⁺ T cells and CCL5 production after antigen stimulation in association with the severity of Chagas heart disease. Peripheral blood cells of Chagas disease (CD) patients grouped as A (asymptomatic, n = 20), B1 [mild chronic chagasic cardiomyopathy (CCC), n = 20], or C (severe CCC, n = 16) were collected and stimulated with T. cruzi antigen for 24 h. Cells and supernatants were harvested and analyzed for cell markers by flow cytometry and CCL5 production by enzyme-linked immunosorbent assay. (A) Frequencies of CCR1⁺ and CCR5⁺ cells and mean fluorescence intensity (MFI) of CCR1 and CCR5 on CD8⁺ T cells; ^##P < 0.01, antigen-stimulated cells from patients in group C vs group A [analysis of variance (ANOVA), Bonferroni posttest]. (B) CCL5 concentrations in supernatants of cell cultures of CD patients grouped as A, B1, and C; **P < 0.01, antigen-stimulated vs nonstimulated cells from patients in group C (ANOVA, Bonferroni posttest); ^##P < 0.01, antigen-stimulated cells from patients of group C vs group A (ANOVA, Bonferroni posttest).

Go to:

Discussion

The present study was carried out in CD patients from an endemic region of Northeast Brazil with epidemiological, social, and economic indicators common to populations exposed to T. cruzi infection in Latin America (44). In this group of patients, CCL5 −403C > T (rs2107538) CT heterozygotes and T carriers were associated with protection against heart disease, whereas other variants at the CCL2, CCL5, CCR1, and CCR5 genes were not associated with the outcome of Chagas heart disease in this population. To shed light on the role of CCL5, signaling via CCR1 and CCR5, in T. cruzi infection, we used an experimental model of CCC. In chronically T. cruzi-infected mice, splenic CCR1⁺CD8⁺ T cells were less inflammatory than CCR5⁺CD8⁺ T cells regarding the TNF/IL-10 balance. Moreover, splenic CD14⁺ macrophages showed segregated and antagonist CCR1⁺IL-10⁺ and CCR5⁺TNF⁺ phenotypes. The findings in CCR5-deficient mice supported the conclusion that CCR5⁺ cells play a role in heart tissue damage. Additionally, selective blockade of CCR1 in CCR5-deficient mice supported a protective role for CCR1⁺ cells in CCC. Finally, T. cruzi antigen stimulation of human CD8⁺ T cells upregulated CCR1 expression and CCL5 production, supporting the conclusion that the putatively beneficial CCL5–CCR1 axis may be repositioned in CD patients.

Myocarditis, which involves inflammatory CD4⁺ and CD8⁺ T cells and macrophages, is associated with severe Chagas heart disease (4, 5). Therefore, it is reasonable to propose that CC-chemokines, which mainly coordinate mononuclear cell migration to injured tissues (11), play a pivotal role in heart colonization by inflammatory cells in cardiopathic CD patients (6). Consistent with the major accumulation of inflammatory macrophages and T cells, CCL2 and CCL5 mRNA levels were upregulated and CCR2⁺, CCR5⁺, and CCL5⁺ cells were detected in the heart tissue of cardiopathic patients (45, 46). These data support studies attempting to associate functional genetic variants of CC-chemokine ligands and receptors with the risk for and severity of CCC. In this scenario, our data do not support a role for the CCL2 SNP rs1024611 in susceptibility to and/or severity of CCC. This finding is discordant with previous data showing that the CCL2 −2518 A allele, which is associated with a low transcriptional level, correlated with susceptibility to CCC in Brazilian case–control association studies with patients born and raised in São Paulo, Minas Gerais and Bahia (23, 26). The CCL5 SNPs rs2107538 and rs2280788 were found to be monomorphic in a Colombian study and did not allow analysis of the influence of these markers in CCC (21). In our group of CD patients born and residing in Northeast Brazil, the frequency of the minor allele of the CCL5 variant rs2280788 (−28G > C) was very low. However, an association of CCL5 rs2107538 (−403C > T) with protection against the development of CCC was observed for CT heterozygotes and T carriers, when cardiopathic with CHF patients (C group) were compared with non-cardiopathic (A group) patients. Case–control studies associated the CCL5 rs2107538 (403 C > T) with both increased risk of (47) and protection against (48) the development of coronary diseases. One possible explanation for the divergence of these associations can be attributed to the ethnic differences in the distribution of the minor allele of this variant. In this sense, data from a study including five different populations (49) described the variation in the frequency of the mutant allele for this gene variant, which was 15% in American Caucasians and 43% in Americans of African descent. These data reinforce the need to replicate the findings of the present study in independent and ethnically distinct populations of CD patients, as well as to extend the analysis to other variants of the CCL5 gene, allowing assessments at the haplotype level. Regarding the functional effect of CCL5 (−403C > T), the CCL5 rs2107538 T allele has been associated with the upregulation of transcription levels of CCL5 (49). However, another study showed that the −403T allele is not able to influence the transcription levels of the CCL5 gene (50). In the present study, the association of the CCL5 rs2107538 −403 gene variant with protection against CCC relied on heterozygote CT and T allele carriers; however, the levels of CCL5 in serum were not correlated with the genotypes. Therefore, to explain the absence of an association of genotype and CCL5 levels in CD patients, one may propose the idea that the −403T single point mutation is not sufficient to overcome other influences controlling CCL5 expression in CD patients. Additionally, one cannot rule out a rapid consumption of this chemokine, considering the increase in expression of CC-chemokine receptors such as CCR5 on inflammatory cells of CD patients (15, 51). Regardless, one should also consider that a genetic polymorphism may not act independently and that multiple changes in a gene may differentially influence the expression and biological features of a molecule. Furthermore, gene expression levels depend on the type of cell in which the gene is expressed and the signals leading to expression.

The increased concentrations of CCL2 and CCL5 in the serum of T. cruzi-infected patients compared with NI residents in the same endemic areas of the State of Pernambuco were not associated with disease outcome or, particularly, with LVEF. Conversely, elevated CCL2 concentrations in the serum of CD patients correlated with worsening cardiac function in the population of Minas Gerais, Southeast Brazil (14). CCL5 concentrations in serum, however, had not been previously addressed in chagasic patients. Regarding the biological role of CC-chemokines, in vitro CCL2 was shown to participate in parasite uptake and killing in mouse macrophages (52). In addition, CCL2 activates CD8⁺ T cells and macrophages and controls cell migration in experimental acute T. cruzi infection (19). Notably, CCL5 has been shown to control parasite growth in human macrophages via induction of nitric oxide (18) and to be essential for parasite burden control in experimental T. cruzi oral infection (53). Conversely, CC-chemokines, such as CCL5, signaling via CCR1/CCR5 have been implicated in the pathophysiology of experimental CCC, fueling cell migration and heart tissue infiltration of nonbeneficial CD8⁺ T cells (16, 17, 27).

CCL5 signals throughout the CC-chemokine receptors CCR1, CCR3, and CCR5 (11). In the present study, in addition to analyzing the CCR5 +59029 (rs1799987) variant in the promoter region, which has been previously associated with a reduced risk of developing CCC in other reports (21–23), we also analyzed CCR1 variants that were not previously explored in CD patients. The CCR5 variant rs1799987 and the CCR1 SNPs (rs3181077, rs1491961 and rs3136672) showed no significant association with CCC outcome. The increased frequency of asymptomatic CD patients showing the CCR5 +59029G allele associated with low CCR5 expression raised the possibility that the decreased CCR5 expression in inflammatory cells infiltrating the heart tissue might protect against the development of CCC (22). In this vein, Brazilian CCC patients with ventricular dysfunction showed an increased frequency of the CCR5 rs1799988CC genotype compared to those without dysfunction (46). However, CCR5 +59029 (rs1799987) did not influence the left ventricular systolic dysfunction in patients with Chagas heart disease in another Brazilian group of patients (24). Therefore, together, these data are not conclusive regarding the influence of CCR5 +59029 (rs1799987) on Chagas heart disease outcomes. In the present study, haplotype analysis of the CCR1–CCR5 cluster showed no association with susceptibility to or severity of CCC. We further observed no correlation of CCL5 levels in serum with the CCL5, CCR1, and CCR5 gene variants studied, supporting the conclusion that CCL5 serum levels may be controlled by other variants of these or other genes, or even that CCL5 serum levels may result from complex parasite-host interactions. Indeed, CCL5 expression by macrophages and cardiomyocytes is triggered by T. cruzi infection and upregulated by cytokines (52, 54).

Our finding supporting the association of CCL5 rs2107538 variant T, which may upregulate CCL5 expression (49), with protection against the development of CCC, led us to question the possible biological pathways for the induction of protection by CCL5 in Chagas heart disease. To shed light on this point, we analyzed the participation of CCL5 and its receptors CCR1 and CCR5 in CCC using an experimental model of C57BL/6 mice infected with the Colombian strain, which reproduces critical aspects of Chagas heart disease (28, 37, 40, 41) and presents elevated levels of CCL5 in serum (55). Increased CCL5 levels were also detected in the cardiac tissue of chronically infected mice, corroborating the detection of enhanced CCL5 mRNA expression in this tissue (56). In models of acute and chronic Chagas heart disease in C3H/He mice, CCL5 signaling via CCR5/CCR1 has been proposed to play a critical role in cell migration and myocardial damage (16, 17). In oral T. cruzi infection, CCL5 is crucial for parasite growth control and mucosal immunity via B-cell activation and antibody production (53). However, the contribution of CC-chemokine receptors to nonbeneficial and/or protective CCL5-mediated interactions had not been completely elucidated (16, 17, 53). Increased frequencies of CCR5⁺ T cells and macrophages have been detected in the peripheral blood of CD patients compared with NI individuals (15, 51). Herein, we showed that in the spleen of chronically T. cruzi-infected mice, the increased frequencies of CCR5⁺ CD8⁺ T cells and CD14⁺ macrophages were associated with a decreased frequency of CCR1⁺ CD8⁺ T cells and CD14⁺ macrophages. In acute T. cruzi infection, the increased frequency of CCR5⁺ cells has been associated with TNF/TNFR1 signaling (57). Therefore, although not addressed in the present study, it is tempting to speculate that the local and/or systemic high TNF levels present in T. cruzi-infected hosts (14, 40) may, directly or indirectly, control CCR5 expression, favoring the CCL5–CCR5 axis, which may fuel the activation/differentiation of CCR5⁺TNF⁺ cells and contribute to a self-sustained scenario. Interestingly, increased frequencies of CCR5⁺TNF⁺ T cells were detected in patients with Chagas heart disease compared to patients with the indeterminate form (15), in a condition with a TNF-enriched systemic inflammatory milieu (14, 42). Particularly, considering the Th1 (TNF⁺, IFNγ⁺) nature of the inflammatory cells infiltrating the heart tissue (4, 58), the increased frequency of asymptomatic patients, compared to patients with the cardiopathic form, with the gene variant CCR5 +59029G allele associated with low CCR5 expression supports the conclusion that reduced CCR5 expression may be beneficial for CD patients (22).

In our model of experimental CCC, a higher frequency of CCR5⁺ than that of CCR1⁺ CD8⁺ T cells was inflammatory (TNF⁺). More importantly, we provide evidence that in NI age-matched mice and in the CCC model in C57BL/6 mice, CD14⁺ macrophages are mostly segregated into CCR1⁺ and CCR5⁺ populations, where CCR1⁺ cells are predominantly IL-10⁺, whereas CCR5⁺ cells are TNF⁺. These data indicate that the condition is innate in these 5- to 6-month-old mice, and it is not drastically influenced by T. cruzi infection. There was, however, an important increase in the numbers of CD14⁺ macrophages in the spleens of T. cruzi-infected mice. These CD14⁺ macrophages were mainly Ly6C^neg F4/80⁺ (either CD11b⁺ or CD11b^neg). Nevertheless, it remains to be clarified whether the T. cruzi parasite and/or intrinsic host molecules induce the activation and expansion of CD14⁺ macrophages. Recently, LPS has been shown to increase the frequencies of splenic CD14⁺ and bone marrow CD14⁺CD11b⁺ macrophages (59), indicating that pathogen molecules may selectively activate macrophage populations.

Studies of CCR1 expression in peripheral cells have not been conducted in chagasic patients; however, increased frequencies of CCR5⁺ CD8⁺ T cells and macrophages have been detected (15, 51). Although a similar analysis of simultaneous labeling for CC-chemokine receptors and cytokine expression is not available for CD patients, cardiopathic patients show a higher percentage of macrophages expressing TNF, whereas macrophages of patients with the indeterminate form are committed to IL-10 production after contact with parasites (60). In chronically T. cruzi-infected patients and mouse models, CD8⁺ T cells and macrophages are major components of the heart inflammatory infiltrate (4, 5, 56). During T. cruzi infection, the frequency of CCR5⁺ cells is precociously increased in the spleen (7 dpi) and later in the blood (14 dpi), while the heart tissue is colonized by inflammatory cells by 28 dpi (16, 61). Indeed, spleen-born CD8⁺ T cells and macrophages are involved in both heart tissue injury and repair (7, 8). Therefore, considering the potential functional antagonistic roles of CCR5⁺ and CCR1⁺ cells, we approached the participation of these cells in CCC by initially using CCR5-deficient mice. The reduction of myocardial injury, assessed by CK-MB activity levels in serum, in CCR5-deficient mice compared with CCR5-sufficient mice suggested that CCR5-mediated interactions were associated with CCC severity. Levels of CK-MB activity in serum have been associated with CCC severity in chronic T. cruzi-infected rhesus monkeys (38), CCC evolution in C57BL/6-infected mice (28) and CCC severity in rats (39) and mice (40, 41). Furthermore, CK-MB is a cardiac biomarker in serum that is associated with Chagas cardiomyopathy and is a predictor of mortality (62). Thus, the demonstration of reduced CK-MB activity in CCR5-deficient mice reinforces the notion that CCR5 mediates a deleterious effect in heart tissue. Interestingly, these T. cruzi-infected CCR5-deficient mice exhibited a reduced parasite load, which could also contribute to reduced myocardial damage. Hence, our data reinforce the conclusion that the CCR5-mediated response is not essential for T. cruzi growth control (16, 17, 53). However, these chronically T. cruzi-infected CCR5-deficient mice presented more intense myocarditis with macrophages, CD4⁺ and CD8⁺ cells. Thus, the beneficial role of CCR5 deficiency may reside in the depletion of CCR5⁺TNF⁺ cells rather than in reduced cell infiltration in heart tissue. Thus, beyond the intensity of heart inflammatory infiltrates, the quality of the immune response associated with myocarditis may determine the outcome of Chagas heart disease. This idea is supported by the previous demonstration that blockade of TNF by antibody administration to chronically infected mice reduced CCC severity (40). Indeed, the deleterious role of CCR5⁺TNF⁺ cells in CCC is also supported by the increased frequency of these cells in the peripheral blood of cardiopathic patients compared to that in patients presenting the indeterminate form of CD (15).

A critical point to be considered is the increase in CCL5 levels in the heart tissue of T. cruzi-infected CCR5-deficient mice, corroborating findings showing elevated CCL5 serum concentrations in orally infected Ccr5^−/− mice (53). In CCR5-deficient mice, CCL5 may signal via CCR1 and CCR3 and play a beneficial role in parasite control and/or have a direct protective action against CCC. This idea is partially supported by in vitro data showing that CCL5 activates human and mouse macrophages, leading to parasite control (18, 52). This initial observation has prompted further explorations to distinguish the participation of CCR1-mediated interactions in myocardial injury in T. cruzi infection. Thus, considering the similar expression of CCR1 in heart tissue and spleen of Ccr5^+/+ and Ccr5^−/− mice, we abrogated CCR1 signaling in CCR5-deficient mice using the selective CCR5/CCR1 antagonist Met-RANTES (43). Abrogation of the protective role of CCR5 deficiency supports the conclusion that CCR1-mediated interactions are involved in protection against myocardial damage in T. cruzi infection. The functional role of CCR1⁺ cells as protectors of myocardial injury is not clear. Regarding the regulatory (IL-10) and inflammatory (TNF) antagonist profiles, our data support that CCR1⁺ CD8⁺ T cells are less inflammatory than CCR5⁺ CD8⁺ T cells. Moreover, in infected mice, splenic CCR1⁺ macrophages are mainly IL10⁺. In these functional property may reside the protective role of CCR1-mediated interaction in CCC. Met-RANTES-treated C57BL/6 mice and CCR5-deficient mice pretherapy showed reduced TNF concentrations in heart tissue. Furthermore, Met-RANTES administration to CCR5-deficient mice resulted in augmented TNF levels in the heart milieu, supporting the conclusion that CCR1⁺ cells may be important for the control of TNF expression in T. cruzi infection. Indeed, in a model of arthritis, CCR1 blockade or depletion enhanced systemic TNF production (63). In Colombian-infected mice, IL-10 limits T. cruzi burden and protects against fatal myocarditis (64). Importantly, IL-10 levels in serum are higher in asymptomatic patients, while TNF levels are higher in cardiopathic CD patients (65). Furthermore, TNF blockade in chronically infected mice favors IL-10 expression, increases the frequency of IL-10⁺ F4/80⁺ macrophages and reverses CCC (40), supporting our hypothesis that the protective role of CCR1⁺ cells may reside in this differential IL-10 profile. Therefore, our present proposal is that IL-10- and TNF-expressing cells, which express CCR1 and CCR5 on the cell surface, respectively, may respond differentially to CCL5 or other CC-chemokines and, therefore, antagonistically act on heart tissue during T. cruzi infection. Therefore, one putative way to favor a beneficial immune response would be to activate CCR1⁺ cells and CCL5 production in T. cruzi-infected individuals. To explore the viability of this idea, we stimulated peripheral blood cells of CD patients with T. cruzi antigens. Indeed, we observed a significant increase in the frequency of CCR1⁺, but not of CCR5⁺, CD8⁺ T cells, upregulated CCR1 expression and increased concentrations of CCL5 in supernatants. These effects were elevated in patients in group C (severe cardiopathy) compared with those in group A (non-cardiopathic). Theoretically, these newly antigen-experienced CD8⁺ T cells gain access to peripheral tissues and sites of inflammation, where they may exert their functions (66). Therefore, our data reinforce the possibility of a repositioning of the immune response toward a protective profile (in the present case, one associated with cell migration and functional properties), which can be achieved by therapeutic vaccine or antigen-driven stimulation, as a feasible strategy to improve the prognosis of CD patients.

Similar to most studies of gene polymorphisms in CD, our study also has some limitations related to sample size. Furthermore, the reduced number or lack of previous studies did not allow comparative analysis with our studied group of patients considering the same genetic markers. Our finding demonstrating a protective effect against CCC for the heterozygote CT and T allele CCL5 rs2107538 variant should be validated in other populations. Additionally, some controversial data with respect to the literature may highlight a multigenic character of CCC, supporting the notion that genetic variants of multiple molecules may contribute small effects that together explain the complex expression of Chagas heart disease. Based on the perspective of our study using the experimental model of CCC, an important feature to be addressed in CD patients is the cell migration phenotype in association with functionality in circulating cells. More broadly, our data revealed that CCR1⁺ and CCR5⁺ CD14⁺ macrophages expressed segregated and antagonist cytokine profiles. Therefore, this antagonistic cell migration profile may become a target of further exploration to comprehend the participation of CD8⁺ T cells and resident or infiltrating spleen-borne macrophages in Chagas heart disease and other cardiac diseases (8). Nevertheless, the data presented herein open a new avenue for the study of cell effector functions and migration profiles, which are apparently susceptible to repositioning after a proper stimulus, with the aim of understanding the involvement of the immune response in Chagas heart disease and improving the prognosis of patients afflicted by this neglected disease.

Go to:

Ethics Statement

This study was carried out in accordance with the recommendations of the Ethics Committees of Fiocruz/RJ (541/09) and PROCAPE/UPE (80210/10). All subjects provided written informed consent in accordance with the Declaration of Helsinki. This study was carried out in strict accordance with the recommendations of the Guide for the Care and Use of Laboratory Animals of the Brazilian National Council of Animal Experimentation (http://www.cobea.org.br/) and Federal Law 11.794 (October 8, 2008). The Institutional Committee for Animal Ethics of Fiocruz (CEUA-Fiocruz-L004/09; LW-10/14) approved all experimental procedures used in the present study. All presented data were obtained from three independent experiments (Experiment Register Books #31 and 57, LBI/IOC-Fiocruz).

Go to:

Author Contributions

Conceived and designed the experiments: JL-V, AMB, LA-A, WO, MM, and AAS. Performed the experiments: JL-V, AMB, LA-A, AAS, IP, LR, VL, AM, AKAS, and AMB. Analyzed the data: AMB, LA-A, VL, and JL-V. Wrote the manuscript: AMB, LA-A, and JL-V. All authors read and revised the manuscript.

Go to:

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling Editor declared a shared affiliation, though no other collaboration, with one of the authors CCC.

Go to:

Acknowledgments

The authors would like to thank all the patients who voluntarily participated in the study, the staff of the House of Chagas (Casa de Chagas) and the Association of Chagas Disease Patients of Pernambuco for their collaboration during patient recruitment and clinical evaluation. The authors would also like to acknowledge the assistance of the nurse Valdinete Paiva (in memoriam) during recruitment, clinical evaluation, and patient care, and the authors thank Ms. Nathalia Vinagre (FAPERJ technician) and Mrs. Marcio Cipitelli (CNPq under-graduate student) for performing some analyses of the initial experiment. The authors are grateful to the Program for Technological Development in Tools for Health (PDTIS-Fiocruz) for the use of the real-time PCR platform of IOC/Fiocruz RJ (RPT09B) and cytometry platform of IAM/Fiocruz-PE (RPT08F).

Go to:

Footnotes

Funding. This work was supported by grants from Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro/FAPERJ (CNE/E-26/101.549/2010; E-26/110.153/2013; E-26/111.709/2013) and the Brazilian Research Council/CNPq (474234/2012-6-Universal; 474926/2012-5-Universal, 474234/2012-6; INCTV, National Institute for Science and Technology for Vaccines; DECIT/MS/CNPq 403979/2012-9; BPP 4296073664961416; PROEP/IOC/CNPq 400146/2011). JL-V and MM are research fellows of the Brazilian Research Council/CNPq and CNE/Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro/FAPERJ. AB was supported as a postdoctoral fellow by the funding agency Conselho Nacional de Desenvolvimento Científico e Tecnológico/CNPq and was a CL/IOC fellow. LA-A was supported as a postdoctoral fellow by PPSUS and PAPD programs funded by CAPES and FAPERJ.

Go to:

Supplementary Material

The Supplementary Material for this article can be found online at https://www.frontiersin.org/articles/10.3389/fimmu.2018.00615/full#supplementary-material.

Click here for additional data file.^{(38K, docx)}

Click here for additional data file.^{(1.0M, tif)}

Click here for additional data file.^{(1.3M, tif)}

Click here for additional data file.^{(79K, tif)}

Click here for additional data file.^{(1007K, tif)}

Click here for additional data file.^{(93K, tif)}

Click here for additional data file.^{(1.2M, tif)}

Click here for additional data file.^{(1.0M, tif)}

Click here for additional data file.^{(2.2M, tif)}

Click here for additional data file.^{(2.2M, tif)}

Go to:

References

1. World Health Organization. Chagas Disease (American Trypanosomiasis). World Health Organization; (2017). Available from: http://www.who.int/mediacentre/factsheets/fs340/en/ (Accessed: November 2, 2017). [Google Scholar]
2. Ribeiro AL, Nunes MP, Teixeira MM, Rocha MO. Diagnosis and management of Chagas disease and cardiomyopathy. Nat Rev Cardiol(2012) 9(10):576–89.10.1038/nrcardio.2012.109 [PubMed] [CrossRef] [Google Scholar]
3. Rassi A, Jr., Marin-Neto JA, Rassi A. Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial. Mem Inst Oswaldo Cruz(2017) 112(3):224–35.10.1590/0074-02760160334 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
4. Reis DD, Jones EM, Tostes S, Lopes ER, Gazzinelli G, Colley DG, et al. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumor necrosis factor-α+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg(1993) 48(5):637–44.10.4269/ajtmh.1993.48.637 [PubMed] [CrossRef] [Google Scholar]
5. Higuchi MD, Reis MM, Aiello VD, Benvenuti LA, Gutierrez PS, Bellotti G, et al. Association of an increase in CD8⁺T-cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg (1997) 56(5):485–9.10.4269/ajtmh.1997.56.485 [PubMed] [CrossRef] [Google Scholar]
6. Cunha-Neto E, Chevillard C. Chagas disease cardiomyopathy: immunopathology and genetics. Mediators Inflamm(2014) 2014:683230.10.1155/2014/683230 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
7. Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, Cortez-Retamozo V, Panizzi P, et al. Identification of splenic reservoir monocytes and their deployment to inflammatory sites. Science(2009) 325(5940):612–6.10.1126/science.1175202 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
8. Epelman S, Liu PP, Mann DL. Role of innate and adaptive immune mechanisms in cardiac injury and repair. Nat Rev Immunol(2015) 15(2):117–29.10.1038/nri3800 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
9. Butcher EC. Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell(1991) 67(6):1033–6.10.1016/0092-8674(91)90279-8 [PubMed] [CrossRef] [Google Scholar]
10. Springer TA. Traffic signals for lymphocyte recirculation and leukocyte emigration: the multi-step paradigm. Cell(1994) 76(2):301–14.10.1016/0092-8674(94)90337-9 [PubMed] [CrossRef] [Google Scholar]
11. Proudfoot AE, Bonvin P, Power CA. Targeting chemokines: pathogens can, why can’t we?Cytokine (2015) 74(2):259–67.10.1016/j.cyto.2015.02.011 [PubMed] [CrossRef] [Google Scholar]
12. Cavalera M, Frangogiannis NG. Targeting the chemokines in cardiac repair. Curr Pharm Des(2014) 20(12):1971–9.10.2174/13816128113199990449 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
13. Qidwai T, Khan MY. Impact of genetic variations in C-C chemokine receptors and ligands on infectious diseases. Hum Immunol(2016) 77(10):961–71.10.1016/j.humimm.2016.06.010 [PubMed] [CrossRef] [Google Scholar]
14. Talvani A, Rocha MO, Barcelos LS, Gomes YM, Ribeiro AL, Teixeira MM. Elevated concentrations of CCL2 and tumor necrosis factor-alpha in chagasic cardiomyopathy. Clin Infect Dis(2004) 38(7):943–50.10.1086/381892 [PubMed] [CrossRef] [Google Scholar]
15. Gomes JA, Bahia-Oliveira LM, Rocha MO, Busek SC, Teixeira MM, Silva JS, et al. Type 1 chemokine receptor expression in Chagas disease correlates with morbidity in cardiac patients. Infect Immun(2005) 73(12):7960–6.10.1128/IAI.73.12.7960-7966 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
16. Marino AP, da Silva A, dos Santos P, Pinto LM, Gazzinelli RT, Teixeira MM, et al. Regulated on activation, normal T-cell expressed and secreted (RANTES) antagonist (Met-RANTES) controls the early phase of Trypanosoma cruzi-elicited myocarditis. Circulation(2004) 110(11):1443–9.10.1161/01.CIR.0000141561.15939.EC [PubMed] [CrossRef] [Google Scholar]
17. Medeiros GA, Silverio JC, Marino AP, Roffe E, Vieira V, Kroll-Palhares K, et al. Treatment of chronically Trypanosoma cruzi-infected mice with a CCR1/CCR5 antagonist (Met-RANTES) results in amelioration of cardiac tissue damage. Microbes Infect(2009) 11(2):264–73.10.1016/j.micinf.2008.11.012 [PubMed] [CrossRef] [Google Scholar]
18. Villalta F, Zhang Y, Bibb KE, Kappes JC, Lima MF. The cysteine-cysteine family of chemokines RANTES, MIP-1alpha, and MIP-1beta induce trypanocidal activity in human macrophages via nitric oxide. Infect Immun(1998) 66(10):4690–5. [PMC free article] [PubMed] [Google Scholar]
19. Paiva CN, Figueiredo RT, Kroll-Palhares K, Silva AA, Silvério JC, Gibaldi D, et al. CCL2/MCP-1 controls parasite burden, cell infiltration, and mononuclear activation during acute Trypanosoma cruziinfection. J Leukoc Biol (2009) 86(5):1239–46.10.1189/jlb.0309187 [PubMed] [CrossRef] [Google Scholar]
20. Stone MJ, Hayward JA, Huang C, E Huma Z, Sanchez J. Mechanisms of regulation of the chemokine-receptor network. Int J Mol Sci(2017) 18(2):E342.10.3390/ijms18020342 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
21. Flórez O, Martín J, González CI. Genetic variants in the chemokines and chemokine receptors in Chagas disease. Hum Immunol(2012) 73(8):852–8.10.1016/j.humimm.2012.04.005 [PubMed] [CrossRef] [Google Scholar]
22. Calzada JE, Nieto A, Beraún Y, Martín J. Chemokine receptor CCR5 polymorphisms and Chagas’ disease cardiomyopathy. Tissue Antigens(2001) 58(3):154–8.10.1034/j.13990039.2001.580302.x [PubMed] [CrossRef] [Google Scholar]
23. Frade AF, Pissetti CW, Ianni BM, Saba B, Lin-Wang HT, Nogueira LG, et al. Genetic susceptibility to Chagas disease cardiomyopathy: involvement of several genes of the innate immunity and chemokine-dependent migration pathways. BMC Infect Dis(2013) 13:587.10.1186/1471-2334-13-587 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
24. de Oliveira AP, Bernardo CR, Camargo AV, Ronchi LS, Borim AA, de Mattos CC, et al. Genetic susceptibility to cardiac and digestive clinical forms of chronic chagas disease: involvement of the CCR5 59029 A/G polymorphism. PLoS One(2015) 10(11):e0141847.10.1371/journal.pone.0141847 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
25. Machuca MA, Suárez EU, Echeverría LE, Martín J, González CI. SNP/haplotype associations of CCR2 and CCR5 genes with severity of chagasic cardiomyopathy. Hum Immunol(2014) 75(12):1210–5.10.1016/j.humimm.2014.09.023 [PubMed] [CrossRef] [Google Scholar]
26. Ramasawmy R, Cunha-Neto E, Fae KC, Martello FG, Müller NG, Cavalcanti VL, et al. The monocyte chemoattractant protein–1 gene polymorphism is associated with cardiomyopathy in human Chagas disease. Clin Infect Dis(2006) 43(3):305–11.10.1086/505395 [PubMed] [CrossRef] [Google Scholar]
27. Silverio JC, Pereira IR, Cipitelli Mda C, Vinagre NF, Rodrigues MM, Gazzinelli RT, et al. CD8+ T-cells expressing interferon gamma or perforin play antagonistic roles in heart injury in experimental Trypanosoma cruzi-elicited cardiomyopathy. PLoS Pathog(2012) 8(4):e1002645.10.1371/journal.ppat.1002645 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
28. Pereira IR, Vilar-Pereira G, Marques V, da Silva AA, Caetano B, Moreira OC, et al. A human type 5 adenovirus-based Trypanosoma cruzitherapeutic vaccine re-programs immune response and reverses chronic cardiomyopathy. PLoS Pathog (2015) 11(1):e1004594.10.1371/journal.ppat.1004594 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
29. Dias JC, Ramos AN, Jr, Gontijo ED, Luquetti A, Shikanai-Yasuda MA, Coura JR, et al. 2nd Brazilian consensus on Chagas disease, 2015. Rev Soc Bras Med Trop(2016) 49(Suppl 1):3–60.10.1590/0037-8682-0505-2016 [PubMed] [CrossRef] [Google Scholar]
30. Andrade JP, Marin Neto JA, Paola AA, Vilas-Boas F, Oliveira GM, Bacal F, et al. I Latin American Guidelines for the diagnosis and treatment of Chagas’ heart disease: executive summary. Arq Bras Cardiol(2011) 96(6):434–42.10.1590/S0066-782X2011000600002 [PubMed] [CrossRef] [Google Scholar]
31. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res(1988) 16(3):1215.10.1093/nar/16.3.1215 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
32. Zingales B, Miles MA, Campbell DA, Tibayrenc M, Macedo AM, Teixeira MM, et al. The revised Trypanosoma cruzisubspecific nomenclature: rationale, epidemiological relevance and research applications. Infect Genet Evol (2012) 12(2):240–53.10.1016/j.meegid.2011.12.009 [PubMed] [CrossRef] [Google Scholar]
33. dos Santos PV, Roffê E, Santiago HC, Torres RA, Marino AP, Paiva CN, et al. Prevalence of CD8(+)alpha beta T-cells in Trypanosoma cruzi-elicited myocarditis is associated with acquisition of CD62L(Low)LFA-1(High)VLA-4(High) activation phenotype and expression of IFN-gamma-inducible adhesion and chemoattractant molecules. Microbes Infect(2001) 3(12):971–84.10.1016/S1286-4579(01)01461-7 [PubMed] [CrossRef] [Google Scholar]
34. Pereira VR, Nakazawa M, Furtado VC, Abath FG, Gomes YM. Immunodiagnosis of chronic Chagas disease using the Tc 46 and Tc 58 antigens. Rev Soc Bras Med Trop(2000) 33(4):367–70.10.1590/S0037-86822000000400006 [PubMed] [CrossRef] [Google Scholar]
35. Acevedo GR, Longhi SA, Bunying A, Sabri N, Atienza A, Zago MP, et al. Methodological approach to the ex vivoexpansion and detection of T. cruzi-specific T-cells from chronic Chagas disease patients. PLoS One (2017) 12(5):e0178380.10.1371/journal.pone.0178380 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
36. Lorena VM, Lorena IM, Braz SC, Melo AS, Melo MF, Melo MG, et al. Cytokine levels in serious cardiopathy of chagas disease after in vitro stimulation with recombinant antigens from Trypanosoma cruzi. Scand J Immunol(2010) 72(6):529–39.10.1111/j.1365-3083.2010.02462.x [PubMed] [CrossRef] [Google Scholar]
37. Vilar-Pereira G, Resende Pereira I, de Souza Ruivo LA, Cruz Moreira O, da Silva AA, Britto C, et al. Combination chemotherapy with suboptimal doses of benznidazole and pentoxifylline sustains partial reversion of experimental Chagas’ heart disease. Antimicrob Agents Chemother(2016) 60(7):4297–309.10.1128/AAC.02123-15 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
38. Carvalho CM, Silverio JC, da Silva AA, Pereira IR, Coelho JM, Britto CC, et al. Inducible nitric oxide synthase in heart tissue and nitric oxide in serum of Trypanosoma cruzi-infected rhesus monkeys: association with heart injury. PLoS Negl Trop Dis(2012) 6(5):e1644.10.1371/journal.pntd.0001644 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
39. Oliveira LG, Kuehn CC, dos Santos CD, Miranda MA, da Costa CM, Mendonça VJ, et al. Protective actions of melatonin against heart damage during chronic Chagas disease. Acta Trop(2013) 128(3):652–8.10.1016/j.actatropica.2013.09.014 [PubMed] [CrossRef] [Google Scholar]
40. Pereira IR, Vilar-Pereira G, Silva AA, Moreira OC, Britto C, Sarmento ED, et al. Tumor necrosis factor is a therapeutic target for immunological unbalance and cardiac abnormalities in chronic experimental Chagas’ heart disease. Mediators Inflamm(2014) 2014:798078.10.1155/2014/798078 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
41. Pereira IR, Vilar-Pereira G, Moreira OC, Ramos IP, Gibaldi D, Britto C, et al. Pentoxifylline reverses chronic experimental Chagasic cardiomyopathy in association with repositioning of abnormal CD8+ T-cell response. PLoS Negl Trop Dis(2015) 9(3):e0003659.10.1371/journal.pntd.0003659 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
42. Alvarado-Arnez LE, Martins AB, Alves SM, Melo G, Lorena VMB, Cardoso CC, et al. Single nucleotide polymorphisms of cytokine-related genes and association with clinical outcome in a Chagas disease case-control study from Brazil. Mem Inst Oswaldo Cruz(2018) 113(6):e170489. [Google Scholar]
43. Chvatchko Y, Proudfoot AE, Buser R, Juillard P, Alouani S, Kosco-Vilbois M, et al. Inhibition of airway inflammation by amino-terminally modified RANTES/CC chemokine ligand 5 analogues is not mediated through CCR3. J Immunol(2003) 171(10):5498–506.10.4049/jimmunol.171.10.5498 [PubMed] [CrossRef] [Google Scholar]
44. Hotez PJ. The poverty-related neglected diseases: why basic research matters. PLoS Biol(2017) 15(11):e2004186.10.1371/journal.pbio.2004186 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
45. Cunha-Neto E, Dzau VJ, Allen PD, Stamatiou D, Benvenutti L, Higuchi ML, et al. Cardiac gene expression profiling provides evidence for cytokinopathy as a molecular mechanism in Chagas’ disease cardiomyopathy. Am J Pathol(2005) 167(2):305–13.10.1016/S0002-9440(10)62976-8 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
46. Nogueira LG, Santos RH, Ianni BM, Fiorelli AI, Mairena EC, Benvenuti LA, et al. Myocardial chemokine expression and intensity of myocarditis in Chagas cardiomyopathy are controlled by polymorphisms in CXCL9 and CXCL10. PLoS Negl Trop Dis(2012) 6(10):e1867.10.1371/journal.pntd.0001867 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
47. Simeoni E, Winkelmann BR, Hoffmann MM, Fleury S, Ruiz J, Kappenberger L, et al. Association of RANTES G-403A gene polymorphism with increased risk of coronary arteriosclerosis. Eur Heart J(2004) 25(16):1438–46.10.1016/j.ehj.2004.05.005 [PubMed] [CrossRef] [Google Scholar]
48. Jang Y, Chae JS, Hyun YJ, Koh SJ, Kim JY, Ko MJ, et al. The RANTES-403G>A promoter polymorphism in Korean men: association with serum RANTES concentration and coronary artery disease. Clin Sci (Lond)(2007) 113(8):349–56.10.1042/CS20070014 [PubMed] [CrossRef] [Google Scholar]
49. Nickel RG, Casolaro V, Wahn U, Beyer K, Barnes KC, Plunkett BS, et al. Atopic dermatitis is associated with a functional mutation in the promoter of the C-C chemokine RANTES. J Immunol(2000) 164:1612–6.10.4049/jimmunol.164.3.1612 [PubMed] [CrossRef] [Google Scholar]
50. An P, Nelson GW, Wang L, Donfield S, Goedert JJ, Phair J, et al. Modulating influence on HIV/AIDS by interacting RANTES gene variants. Proc Natl Acad Sci U S A(2002) 99(15):10002–7.10.1073/pnas.142313799 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
51. Talvani A, Rocha MO, Ribeiro AL, Correa-Oliveira R, Teixeira MM. Chemokine receptor expression on the surface of peripheral blood mononuclear cells in Chagas disease. J Infect Dis(2004) 189(2):214–20.10.1086/380803 [PubMed] [CrossRef] [Google Scholar]
52. Aliberti JC, Machado FS, Souto JT, Campanelli AP, Teixeira MM, Gazzinelli RT, et al. Beta-chemokines enhance parasite uptake and promote nitric oxide-dependent microbiostatic activity in murine inflammatory macrophages infected with Trypanosoma cruzi. Infect Immun(1999) 67(9):4819–26. [PMC free article] [PubMed] [Google Scholar]
53. Sullivan NL, Eickhoff CS, Zhang X, Giddings OK, Lane TE, Hoft DF. Importance of the CCR5-CCL5 axis for mucosal Trypanosoma cruziprotection and B cell activation. J Immunol (2011) 187(3):1358–68.10.4049/jimmunol.1100033 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
54. Machado FS, Martins GA, Aliberti JC, Mestriner FL, Cunha FQ, Silva JS. Trypanosoma cruzi-infected cardiomyocytes produce chemokines and cytokines that trigger potent nitric oxide-dependent trypanocidal activity. Circulation(2000) 102(24):3003–8.10.1161/01.CIR.102.24.3003 [PubMed] [CrossRef] [Google Scholar]
55. Shrestha D, Bajracharya B, Paula-Costa G, Salles BC, Leite AL, Menezes AP, et al. Expression and production of cardiac angiogenic mediators depend on the Trypanosoma cruzi-genetic population in experimental C57BL/6 mice infection. Microvasc Res(2017) 110:56–63.10.1016/j.mvr.2016.12.002 [PubMed] [CrossRef] [Google Scholar]
56. Talvani A, Ribeiro CS, Aliberti JC, Michailowsky V, Santos PV, Murta SM, et al. Kinetics of cytokine gene expression in experimental chagasic cardiomyopathy: tissue parasitism and endogenous IFN-gamma as important determinants of chemokine mRNA expression during infection with Trypanosoma cruzi. Microbes Infect(2000) 2(8):851–66.10.1016/S1286-4579(00)00388-9 [PubMed] [CrossRef] [Google Scholar]
57. Kroll-Palhares K, Silvério JC, Silva AA, Michailowsky V, Marino AP, Silva NM, et al. TNF/TNFR1 signaling up-regulates CCR5 expression by CD8⁺T lymphocytes and promotes heart tissue damage during Trypanosoma cruzi infection: beneficial effects of TNF-alpha blockade. Mem Inst Oswaldo Cruz (2008) 103(4):375–85.10.1590/S0074-02762008000400011 [PubMed] [CrossRef] [Google Scholar]
58. Abel LC, Rizzo LV, Ianni B, Albuquerque F, Bacal F, Carrara D, et al. Chronic Chagas’ disease cardiomyopathy patients display an increased IFN-gamma response to Trypanosoma cruziinfection. J Autoimmun (2001) 17(1):99–108.10.1006/jaut.2001.0523 [PubMed] [CrossRef] [Google Scholar]
59. Hsueh PT, Liu CL, Wang HH, Ni WF, Chen YL, Liu JK. A comparison of the immunological potency of Burkholderia lipopolysaccharides in endotoxemic BALB/c mice. Microbiol Immunol(2016) 60(11):725–39.10.1111/1348-0421.12450 [PubMed] [CrossRef] [Google Scholar]
60. Souza PE, Rocha MO, Rocha-Vieira E, Menezes CA, Chaves AC, Gollob KJ, et al. Monocytes from patients with indeterminate and cardiac forms of Chagas’ disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun(2004) 72(9):5283–91.10.1128/IAI.72.9.5283-5291.2004 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
61. Silva AA, Roffê E, Santiago H, Marino AP, Kroll-Palhares K, Teixeira MM, et al. Trypanosoma cruzi-triggered meningoencephalitis is a CCR1/CCR5-independent inflammatory process. J Neuroimmunol(2007) 184(1–2):156–63.10.1016/j.jneuroim.2006.12.013 [PubMed] [CrossRef] [Google Scholar]
62. Sherbuk JE, Okamoto EE, Marks MA, Fortuny E, Clark EH, Galdos-Cardenas G, et al. Biomarkers and mortality in severe Chagas cardiomyopathy. Glob Heart(2015) 10(3):173–80.10.1016/j.gheart.2015.07.003 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
63. Amat M, Benjamim CF, Williams LM, Prats N, Terricabras E, Beleta J, et al. Pharmacological blockade of CCR1 ameliorates murine arthritis and alters cytokine networks in vivo. Br J Pharmacol(2006) 149(6):666–75.10.1038/sj.bjp.0706912 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
64. Roffê E, Rothfuchs AG, Santiago HC, Marino AP, Ribeiro-Gomes FL, Eckhaus M, et al. IL-10 limits parasite burden and protects against fatal myocarditis in a mouse model of Trypanosoma cruziinfection. J Immunol (2012) 188(2):649–60.10.4049/jimmunol.1003845 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
65. Sousa GR, Gomes JA, Fares RC, Damásio MP, Chaves AT, Ferreira KS, et al. Plasma cytokine expression is associated with cardiac morbidity in Chagas disease. PLoS One(2014) 9(3):e87082.10.1371/journal.pone.0087082 [PMC free article] [PubMed] [CrossRef] [Google Scholar]
66. Weninger W, Manjunath N, von Andrian UH. Migration and differentiation of CD8⁺T-cells. Immunol Rev (2002) 186:221–33.10.1034/j.1600-065X.2002.18618.x [PubMed] [CrossRef] [Google Scholar]

Articles from Frontiers in Immunology are provided here courtesy of Frontiers Media SA